Clinical Trials
Zotiraciclib is advancing in development as a single agent and in combination with TMZ across glioma patient segments.
NCI Phase 1b (NCT02942264)
Patient segment
Regimen
Recurrent glioblastoma and anaplastic astrocytoma
Zotiraciclib + temozolomide combination therapy
EORTC Phase 1b (NCT03224104)
Patient segment
Regimen
First-line methylated and unmethylated GBM (IDH wt, ≥65 years old, and ineligible for standard chemoradiotherapy), recurrent GBM
Zotiraciclib + radiation (unmethylated)
Zotiraciclib + TMZ (methylated)
Zotiraciclib single agent (recurrent GBM)
Adastra is rapidly advancing the development of zotiraciclib in high-grade gliomas.
While development is currently focused on brain cancer, there is a mechanistic rationale for use in many additional tumor types, such as hepatocellular carcinoma (HCC) and triple-negative breast cancer (TNBC).